3SBio Revenue

3SBio had revenue of 4.36B CNY in the half year ending June 30, 2025, with 15.11% growth. This brings the company's revenue in the last twelve months to 9.07B, up 7.75% year-over-year. In the year 2024, 3SBio had annual revenue of 9.11B with 16.53% growth.

Revenue (ttm)

9.07B CNY

Revenue Growth

+7.75%

P/S Ratio

7.00

Revenue / Employee

1.63M CNY

Employees

5,577

Market Cap

69.56B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	9.11B	1.29B	16.53%
Dec 31, 2023	7.82B	950.20M	13.84%
Dec 31, 2022	6.87B	483.73M	7.58%
Dec 31, 2021	6.38B	794.37M	14.22%
Dec 31, 2020	5.59B	269.55M	5.07%
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro
Dec 31, 2015	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
BeOne Medicines AG	35.81B
Hansoh Pharmaceutical Group Company	14.45B
JD Health International	71.34B
Innovent Biologics	12.52B
WuXi Biologics	21.98B
Sino Biopharmaceutical	33.49B
Akeso	2.75B
Sichuan Kelun-Biotech Biopharmaceutical	1.64B

Revenue Rankings

3SBio News

2 months ago - Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug - South China Morning Post
4 months ago - Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma - Benzinga
4 months ago - Pfizer Thinks Bigger With 3SBio Deal - Seeking Alpha
4 months ago - Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China - Investopedia
4 months ago - Pfizer strikes deal with China's 3SBio to license cancer drug - CNBC
4 months ago - Pfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal - Benzinga

More News